CHC – The Cancer & Hematology Centers

KSQ-4279-1101 (KSQ Therapeutics)

Description:   A Phase 1 Study of KSQ-4279 Alone and in Combination in Patients with Advanced Solid Tumors.

Target Patient Population:  Solid Tumors

Study Design:  Study drug is given orally daily.   Currently in monotherapy in dose escalation.  Phase 2 will follow with expansion in combinations with mFOLFOX, Gem/Carbo and Olaparib combinations.